Myovant Sciences Ltd. (MYOV)
Stock Price:
$15.24 USD
-0.58 (-3.67%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.37B |
| Revenue (ttm) |
33.33M |
| Net Income (ttm) |
-253.95M |
| Shares Out |
90.15M |
| EPS (ttm) |
-2.85 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$15.24 |
| Previous Close |
$15.82 |
| Change ($) |
-0.58 |
| Change (%) |
-3.67% |
| Day's Open |
15.70 |
| Day's Range |
15.01 - 15.96 |
| Day's Volume |
468,571 |
| 52-Week Range |
4.14 - 23.04 |
More Stats
| Market Cap |
1.37B |
| Enterprise Value |
1.48B |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
90.15M |
| Float |
31.79M |
| EPS (basic) |
-2.85 |
| EPS (diluted) |
-2.85 |
| FCF / Share |
-2.44 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.00M |
| Short Ratio |
1.26 |
| Short % of Float |
6.30% |
| Beta |
2.59 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
41.22 |
| PB Ratio |
70.01 |
| Revenue |
33.33M |
| Operating Income |
-243.30M |
| Net Income |
-253.95M |
| Free Cash Flow |
-217.46M |
| Net Cash |
-106.16M |
| Net Cash / Share |
-1.18 |
| Gross Margin |
100.00% |
| Operating Margin |
-729.90% |
| Profit Margin |
-761.80% |
| FCF Margin |
-652.37% |
| ROA |
-76.58% |
| ROE |
-622.01% |
| ROIC |
-197.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
6 |
| Overweight |
1 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$30.86*
(102.49% upside)
Low
20.0
Current: $15.24
High
55.0
Target: 30.86
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -275 | -265 | -141 | -55.86 |
| Net Income | -289 | -274 | -143 | -83.44 |
| Shares Outstanding | 85.84 | 66.91 | 59.52 | 49.18 |
| Earnings Per Share | -3.37 | -4.09 | -2.41 | -1.70 |
| Operating Cash Flow | -221 | -224 | -117 | -18.22 |
| Capital Expenditures | -1.10 | -1.24 | -0.60 | -0.97 |
| Free Cash Flow | -222 | -225 | -118 | -19.18 |
| Cash & Equivalents | 79.64 | 156 | 109 | 181 |
| Total Debt | 126 | 99.38 | 43.62 | - |
| Net Cash / Debt | -46.57 | 56.69 | 65.00 | 181 |
| Assets | 106 | 173 | 119 | 185 |
| Liabilities | 214 | 169 | 81.37 | 18.50 |
| Book Value | -108 | 4.33 | 37.73 | 167 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Myovant Sciences Ltd. |
| Country |
United Kingdom |
| Employees |
214 |
| CEO |
Lynn Seely |
Stock Information
| Ticker Symbol |
MYOV |
| Stock Exchange |
New York Stock Exchange |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSE: MYOV |
| IPO Date |
October 27, 2016 |
Description
Myovant Sciences, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.